Satellos Announces Participation in September 2024 Investor Conferences
2024年9月5日 - 8:00PM
ビジネスワイヤ(英語)
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX:
MSCL) (OTCQB: MSCLF), a public biotech company developing new small
molecule therapeutic approaches to improve the treatment of muscle
diseases and disorders, announced today that Mr. Frank Gleeson,
Co-founder and CEO of Satellos will participate in fireside chats
and one-on-one meetings during the following conferences taking
place in New York City along with Ms. Elizabeth Williams, CFO of
Satellos.
H.C. Wainwright 26th Annual Global Investment Conference
Format: Fireside Chat Date: Wednesday, September 11th
at 8:00 a.m. ET
Cantor 2024 Global Healthcare Conference Format:
Fireside Chat Date: Thursday, September 19th at 9:45 a.m.
ET
The fireside chats will be available via live webcast on the
Events and Presentations page in the Investors section of the
Company’s website and a replay will be available following the
presentations.
About Satellos Bioscience Inc.
Satellos is a publicly traded biotechnology company dedicated to
developing life-improving medicines to treat degenerative muscle
diseases. Satellos has incorporated breakthrough research in muscle
stem cell polarity into a proprietary discovery platform, called
MyoReGenXTM, to identify degenerative muscle diseases where
deficits in this process affect muscle regeneration and are
amenable to therapeutic intervention. With this platform, Satellos
is building a pipeline of novel therapeutics to correct muscle stem
cell polarity and promote the body’s innate muscle repair and
regeneration process. The Company’s lead program is an oral, small
molecule drug candidate in development as a potential
disease-modifying treatment for Duchenne muscular dystrophy.
Satellos is headquartered in Toronto, Ontario. For more
information, visit www.satellos.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240905313758/en/
Investors: Liz Williams, ir@satellos.com Business Development:
Ryan Mitchell, Ph.D., bd@satellos.com Media: Jessica Yingling,
Ph.D., jessica@litldog.com, +1.858.344.8091
Satellos Bioscience (TSX:MSCL)
過去 株価チャート
から 11 2024 まで 12 2024
Satellos Bioscience (TSX:MSCL)
過去 株価チャート
から 12 2023 まで 12 2024